1257 Augmenting post-market surveillance of serious drug-induced adverse events with artificial intelligence (AI)-aggregated case reports: proof-of-concept for PD-1/PD-L1 inhibitors for NSCLC
1257 Augmenting post-market surveillance of serious drug-induced adverse events with artificial intelligence (AI)-aggregated case reports: proof-of-concept for PD-1/PD-L1 inhibitors for NSCLC
PDF